Skip to content

Arwr stock zacks

Arwr stock zacks

Arrowhead Pharmaceuticals, Inc. (ARWR) Latest Stock News ... Get the latest Arrowhead Pharmaceuticals, Inc. (ARWR) stock news and headlines to help you in your trading and investing decisions. Arrowhead Pharma shares halted (NASDAQ:ARWR) | Seeking Alpha Oct 04, 2018 Arrowhead Pharmaceuticals, Inc. (ARWR) Dividend ... - Nasdaq

Jun 05, 2020

ARWR Arrowhead $35.91 / -0.41 (-1.13%). 05/07/20 Arrowhead discloses COVID-19 development program 05/01/20 Arrowhead COO Bruce Given retires 04/10/20 Arrowhead files for clearance to begin Phase 1/2 cystic fibrosis trial Arrowhead Pharmaceuticals Inc. ARWR - Quotes, Financials ... Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them.

The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share. The drug developer posted revenue of $23.5 million in the period, which topped Street forecasts. Six analysts surveyed by Zacks expected $21.9 million.

ARWR Stock | ARROWHEAD PHARMACEUTICALS Stock Price … ARWR: Get the latest Arrowhead Pharmaceuticals stock price and detailed information including ARWR news, historical charts and realtime prices. ARWR Stock Rating and Data | Arrowhead Pharmaceuticals ...

Zacks Investment Research Page 2 scr.zacks.com WHATS NEW Janssen Collaboration Announced on October 4th and closed at the end of the same month, ARWR received $250M upfront upon closing and is eligible for another $3.5B in potential additional milestones and for royalties on eventual commercial sales.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat ARWR Arrowhead Research Corp. — Stock Price and Discussion ... Arrowhead Research Corp. ARWR 35.74 1.67 (4.90%). NASDAQ Updated Jun 8, 2020 8:00 PM Stock Picks, Stock Market Investing | Seeking Alpha

ARWR Stock Price | Arrowhead Pharmaceuticals Corp. Stock ...

ARWR - Arrowhead Pharma Stock Price - Barchart.com Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $34.86 to a high of $36.38. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of ARWR stock: Arrowhead Pharmaceuticals Inc Arrowhead Pharmaceuticals Inc's stock rating is based on fundamental analysis. Don't miss ARWR stock next rating changes

Apex Business WordPress Theme | Designed by Crafthemes